SWOG clinical trial number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Abbreviated Title
PRAGMATICA - LUNG
Status Notes
S2302 will permanently closed to accrual effective December 20, 2024, at 12:00 p.m. Pacific Time.
Activated
03/06/2023
Closed
12/20/2024
Research committees
Lung Cancer
Treatment
MK-3475
Ramucirumab
Other Study Materials
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
S2414
SWOG Clinical Trial Number
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
1% Accrual
Accrual
1%
Open
Phase
A082002
SWOG Clinical Trial Number
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
CTSU/NRG-LU007
SWOG Clinical Trial Number
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open